Inventro S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2023-02-08
Share capital
100,165.00 PLN
Average employment (people)
2 (2025)
Activity description

Inventro combines AI models with experimental biology for oncology drug discovery. It predicts molecular targets and ranks compounds for follow-up, then uses laboratory experiments to measure compound activity and cellular responses. Its scientists interpret the evidence to help research teams decide what to advance, retest or stop.

Registered address
ul. Złota 2/19, 15-016 Białystok, Poland
Email
Electronic delivery address
AE:PL-61488-48693-TEEJU-18

Financials

Revenue history (in k)

From the notes

Profit allocationLoss covered
Loans and borrowings$349,824
Revenue structureusługi
R&D costs$112,092
Events after the balance sheet dateYes
Shareholders
  • osoba fizyczna 48.5%
  • osoba fizyczna 48.5%
  • pozostali akcjonariusze 3%

Filing timeliness

2 of 3 financial statements were filed late (the longest delay 308 days for 2023). All were audited by a statutory auditor.

  • 202514/10/2026
  • 202406/06/2025
  • 202319/05/2025
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Scientific research and development1,239 / 1,943
Top 64%
City · Białystok2,538 / 3,168
Top 80%
Voivodeship · Podlaskie4,664 / 5,638
Top 83%
Country · Poland242,666 / 297,266
Top 82%

Results vs industry

Revenue
This companyUSD 25.97kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -42.80kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 44.13kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 344.48kMedianUSD 134.71kAverageUSD 3.04m

Offer

  • Molecular target prediction
  • Compound prioritisation
  • Compound activity testing
  • Cellular response testing
  • High-content imaging
  • Experimental validation

Websites

The site is available in: Polish and English.

  • inventro.coINVENTRO | AI-enabled oncology drug discovery
    LiteSpeed

Authorized Representatives

Tomasz Piotr Nowowiejski age 57 – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board is authorised independently to represent the company. In the case of a multi-member management board being appointed, joint action of two members of the management board or one member of the management board jointly with a commercial proxy is required to represent the company.

Supervisory board

Beata Szukajt age 41 – Supervisory Board Member
Mariusz Grotek age 36 – Supervisory Board Member
Monika Szamborska age 35 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2023-03-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid for research and development projects: industrial research
–
Aid for research and development projects: experimental development
–

European Funds

ProjectEU co-financing
High-throughput, multiparametric platform for testing drug candidates and drugs using ex vivo tumor models
$2.1M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Digital Pathology Team sp. z o.o.
Orphinic Scientific S.A.
Onconick sp. z o.o.
Biolabic sp. z o.o.
Cannamedai S.A.
Pioligon sp. z o.o.
DR Joanna Sanford sp. k.
Nanovelos S.A.
Skinai sp. z o.o.
Oncotherics Poland S.A.

Change history

DateEvent
2026-09-17Share capital increase
2026-08-07Address change
2023-03-02PKD change
2023-02-08Entered in the register

FAQ

Last updated: 2026-10-14